Eton Pharmaceuticals, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Eton Pharmaceuticals, Inc. (ETON) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $2.82 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-13
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.82M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $3.98M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.00M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.00M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $2.82M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $3.98M 10-Q · filed 2026-05-14 |
| 2025-09-30 | $1.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $3.00M 10-Q · filed 2025-05-13 |
| 2024-09-30 | $266.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $534.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $800.00K 10-Q · filed 2024-05-09 |
| 2023-09-30 | $181.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $363.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $544.00K 10-Q · filed 2023-05-11 |
| 2022-09-30 | $219.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $238.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $469.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |